Ignite Creation Date:
2024-05-06 @ 2:32 PM
Last Modification Date:
2024-10-26 @ 1:32 PM
Study NCT ID:
NCT04344678
Status:
RECRUITING
Last Update Posted:
2023-01-18
First Post:
2020-04-09
Brief Title:
The Phosphodiesterase 5 Inhibitor Sildenafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients
Sponsor:
Sadat City University
Organization:
Sadat City University
Study Overview
Official Title:
The Phosphodiesterase 5 Inhibitor Sildenafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients Randomized Double-Blind Placebo-Controlled Trial
Status:
RECRUITING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Antidepressant-like effects of sildenafil to its ability to modulate transduction pathways responsible for neuroplasticity Treatment with sildenafil was shown to be PKG-dependent and lead to increased expression of cGMP pCREB BDNF and VGF in the hippocampus and prefrontal cortex PFC brain areas relevant to mood disorders pathophysiology Sildenafil produces antidepressant-like effects by inhibiting oxidative stress in the hippocampus and by decreasing the levels of IL-1β in the hippocampus and striatum
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None